Daring to Make a Difference

Join Revance

Who Said We Can’t Change the Expectations of Neuromodulation?

Aesthetics

Our lead investigational product redefines how a neuromodulator may perform, endure and deliver.

Learn More

Therapeutics

We are developing treatments to transform patient experiences in muscle movement, neurology, musculoskeletal, and more.

Learn more

Aesthetics: Facts, Figures, & Trends

908% increase in aesthetic procedures with botulinum toxin injections since 2000¹

Explore Aesthetics

Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA Read More

Our Latest

Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines Read More

ALL NEWS

Our Latest

Revance Provides Corporate Update and Anticipated Milestones for 2020 Read More

Our Latest

Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology Read More

OUR LATEST

STOCK QUOTE

$21.78 EXCHANGE NYSE (US DOLLAR)

0.54 VOLUME 656,214

Price could be delayed by up to 15 mins

INVESTOR INFORMATION MORE INFO

STOCK QUOTE

$21.78 EXCHANGE NYSE (US DOLLAR)

0.54 VOLUME 656,214

Price could be delayed by up to 15 mins

1. The American Society of Plastic Surgeons. 2018 Plastic Surgery Statistic Report Available at: https://www.plasticsurgery.org/documents/News/Statistics/2018/plastic-surgery-statistics-full-report-2018.pdf. Accessed July 2019

Daring to Make a Difference

Who Said We Can’t Change the Expectations of Neuromodulation?

Aesthetics: Facts, Figures, & Trends

Aesthetics

Therapeutics

Investors

Company

News

Careers

Contact